PFIZER REPORTS POSITIVE CLINICAL DATA FOR BCMA-CD3 BISPECIFIC ANTIBODY (PF-06863135) IN MULTIPLE MYELOMA
The FINANCIAL -- Pfizer Inc. (NYSE:PFE) announced safety and clinical response results from the ongoing Phase 1 study (NCT03269136) for PF-06863135, ...